[1] Cohen M S, Chen Y Q, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy[J]. N Engl J Med, 2011, 365(6): 493-505.
[2] Lohse N, Obel N.Update of Survival for Persons With HIV Infection in Denmark[J]. Ann Intern Med, 2016, 165(10): 749-750.
[3] Costagliola D.Demographics of HIV and aging[J]. Curr Opin HIV AIDS, 2014, 9(4): 294-301.
[4] Sackoff J E, Hanna D B, Pfeiffer M R, et al.Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City[J]. Ann Intern Med, 2006, 145(6): 397-406.
[5] Currier J S, Taylor A, Boyd F, et al.Coronary heart disease in HIV-infected individuals[J]. J Acquir Immune Defic Syndr, 2003, 33(4): 506-512.
[6] Mothe B, Perez I, Domingo P, et al.HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain[J]. Curr HIV Res, 2009, 7(6): 597-600.
[7] Yuan G, Al-Shali K Z, Hegele R A. Hypertriglyceridemia: its etiology, effects and treatment[J]. CMAJ, 2007, 176(8): 1113-1120.
[8] Chapman M J, Ginsberg H N, Amarenco P, et al.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management[J]. Eur Heart J, 2011, 32(11): 1345-1361.
[9] Hegele R A, Ginsberg H N, Chapman M J, et al.The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management[J]. Lancet Diabetes Endocrinol, 2014, 2(8): 655-666.
[10] Souza S J, Luzia L A, Santos S S, et al.Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review[J]. Rev Assoc Med Bras (1992), 2013, 59(2): 186-198.
[11] Grinspoon S, Carr A.Cardiovascular risk and body-fat abnormalities in HIV-infected adults[J]. N Engl J Med, 2005, 352(1): 48-62.
[12] Funderburg N T, Mehta N N.Lipid Abnormalities and Inflammation in HIV Inflection[J]. Curr HIV/AIDS Rep, 2016, 13(4): 218-225.
[13] Bernal E, Masia M, Padilla S, et al.High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition[J]. AIDS Patient Care STDS, 2008, 22(7): 569-575.
[14] Llibre J M, Domingo P, Palacios R, et al.Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir[J]. AIDS, 2006, 20(10): 1407-1414.
[15] da Cunha J, Maselli L M, Stern A C, et al. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs[J]. World J Virol, 2015, 4(2): 56-77.
[16] Calmy A, Montecucco F, James R W.Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals[J]. Curr Vasc Pharmacol, 2015, 13(2): 167-172.
[17] Cobos Jimenez V, Booiman T, de Taeye S W, et al. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons[J]. Sci Rep, 2012, 2(10): 763.
[18] Vaidya S A, Korner C, Sirignano M N, et al.Tumor necrosis factor alpha is associated with viral control and early disease progression in patients with HIV type 1 infection[J]. J Infect Dis, 2014, 210(7): 1042-1046.
[19] Nguemaim N F, Mbuagbaw J, Nkoa T, et al.Serum lipid profile in highly active antiretroviral therapy-naive HIV-infected patients in Cameroon: a case-control study[J]. HIV Med, 2010, 11(6): 353-359.
[20] Kim J Y, Zaoutis T, Chu J, et al.Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study[J]. Pharmacoepidemiol Drug Saf, 2009, 18(7): 589-594.
[21] Bunupuradah T, van der Lugt J, Kosalaraksa P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks[J]. Antivir Ther, 2009, 14(2): 241-248.
[22] Friis-Moller N, Thiebaut R, Reiss P, et al.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study[J]. Eur J Cardiovasc Prev Rehabil, 2010, 17(5): 491-501.
[23] Tungsiripat M, Kitch D, Glesby M J, et al.A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206[J]. AIDS, 2010, 24(11): 1781-1784.
[24] Vigano A, Aldrovandi G M, Giacomet V, et al.Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children[J]. Antivir Ther, 2005, 10(8): 917-924.
[25] Floridia M, Tamburrini E, Ravizza M, et al.Lipid profile during pregnancy in HIV-infected women[J]. HIV Clin Trials, 2006, 7(4): 184-193.
[26] Aurpibul L, Puthanakit T, Lee B, et al.Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy[J]. Antivir Ther, 2007, 12(8): 1247-1254.
[27] Srinivasa S, Grinspoon S K.Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients[J]. Eur J Endocrinol, 2014, 170(5): R185-202.
[28] Lake J E, Currier J S.Metabolic disease in HIV infection[J]. Lancet Infect Dis, 2013, 13(11): 964-975.
[29] Group S-L S, Boyd M A, Kumarasamy N, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study[J]. Lancet, 2013, 381(9883): 2091-2099.
[30] Eron J J, Young B, Cooper D A, et al.Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials[J]. Lancet, 2010, 375(9712): 396-407.
[31] Rockstroh J K, DeJesus E, Lennox J L, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK[J]. J Acquir Immune Defic Syndr, 2013, 63(1): 77-85.
[32] Lennox J L, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial[J]. Lancet, 2009, 374(9692): 796-806.
[33] Lennox J L, Dejesus E, Berger D S, et al.Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses[J]. J Acquir Immune Defic Syndr, 2010, 55(1): 39-48.
[34] Rockstroh J K, Lennox J L, Dejesus E, et al.Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK[J]. Clin Infect Dis, 2011, 53(8): 807-816.
[35] Huesgen E, Burgos R, Goldstein D A, et al.Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen[J]. Antivir Ther, 2012, 17(7): 1385-1388. |
